CPT code 83970 – Parathyroid hormone billing guide

Key Takeaways

CPT Code 83970 reports quantitative intact PTH (parathormone) testing on serum or plasma – not intraoperative PTH monitoring, which uses a different code.

Coverage under Medicare LCD L34018 requires a supporting ICD-10-CM diagnosis; a non-covered or missing code is the leading denial trigger for this code.

The 2026 Medicare Clinical Laboratory Fee Schedule sets the national payment rate; commercial payer rates vary and contracted rates can differ a lot.

Practice management software like Pabau supports correct code and diagnosis pairing, reducing 83970 denials at the point of order entry.

CPT Code 83970: official descriptor, code range, and test type

CPT Code 83970 carries the official AMA descriptor “Parathormone (parathyroid hormone).” It sits within the Chemistry Procedures section of the CPT code set, spanning codes 82000 through 84999. According to the American Medical Association’s CPT code set, this section covers quantitative chemical analyses performed on body specimens. For 83970 specifically, that means a quantitative immunoassay measurement of intact PTH (iPTH, also called PTH 1-84) on a serum or plasma specimen.

Other hormone assays in that range are also paid under the Medicare Clinical Laboratory Fee Schedule. CPT code 83002 for luteinizing hormone is one example.

Two distinctions matter for correct code selection. First, 83970 covers standard outpatient or inpatient PTH measurement – not intraoperative PTH monitoring performed during parathyroid surgery, which uses a separate code. Second, it covers parathyroid hormone itself, not parathyroid hormone-related protein (PTHrP), which is a distinct analyte billed separately. Coders who blur these lines generate avoidable denials or, worse, overpayments subject to audit recovery.

Understanding the full scope of medical billing workflows for laboratory codes helps billing staff apply these distinctions consistently across the revenue cycle.

Clinical indications: when is PTH lab testing medically necessary?

PTH testing is medically necessary when a clinician needs to identify the cause of abnormal calcium levels. Clinicians also use it to monitor a known parathyroid disorder, or track mineral metabolism in kidney disease. Medicare’s LCD L34018 and most commercial payer policies recognize a defined set of clinical scenarios. The ordering provider’s documentation must reflect each indication – a lab order alone does not establish medical necessity.

• Hypercalcemia workup: Elevated serum calcium prompts PTH measurement to distinguish primary hyperparathyroidism (PTH elevated or inappropriately normal) from non-PTH-mediated causes.
• Hypocalcemia evaluation: Low calcium with associated PTH level helps differentiate hypoparathyroidism from vitamin D deficiency or other causes.
• Primary hyperparathyroidism diagnosis and monitoring: PTH is central to diagnosing primary hyperparathyroidism and to post-parathyroidectomy monitoring.
• Secondary and tertiary hyperparathyroidism in chronic kidney disease (CKD): Per NKF KDIGO guidelines, PTH monitoring frequency scales with CKD stage. This is one of the highest-volume indication categories for 83970.
• Pre- and post-parathyroidectomy assessment: PTH values before surgery establish baseline; post-operative drops confirm successful resection.
• Osteoporosis workup: PTH is part of the secondary cause evaluation for unexplained low bone density.
• Vitamin D deficiency assessment: Elevated PTH in the setting of low 25-OH vitamin D (CPT 82306) confirms secondary hyperparathyroidism from nutritional deficiency.

Once those results confirm primary hyperparathyroidism and surgery is planned, the workup moves to preoperative localization. The parathyroid planar imaging that pinpoints the overactive gland is billed under 78070, with its own documented indication.

Covered ICD-10-CM diagnosis codes for CPT 83970

A non-covered or absent ICD-10-CM diagnosis code is the single most common denial trigger for 83970 claims. The table below lists the primary covered codes under Medicare LCD L34018 and major commercial payer policies. Note that covered code lists can vary by MAC jurisdiction and payer; always verify against the specific payer’s LCD or coverage bulletin before billing.

Cross-checking a proposed diagnosis against the covered code list at the point of order entry is a reliable check. It confirms the payer recognizes the diagnosis before you submit the claim.

Medicare LCD L34018 and CMS Article A57122: coverage rules

LCD L34018 (titled “Parathormone”) is the CMS Local Coverage Determination that governs Medicare payment for 83970. CMS Article A57122 is the companion billing and coding article that provides documentation and submission instructions specific to this code. Together they define what coverage includes and excludes. They also set how often you can bill the test per benefit period, and what records must support each claim.

Key provisions billing staff need to track:

• Frequency limits for CKD monitoring: LCD L34018 limits PTH testing frequency for CKD patients based on disease stage. Tests ordered more frequently than the LCD permits require an Advance Beneficiary Notice (ABN). The patient must want to proceed and understand they may bear the cost.
• Contractor-specific coverage lists: Each Medicare Administrative Contractor (MAC) maintains its own covered ICD-10 code list. The BCBS of North Carolina coverage policy for parathyroid hormone testing specifically addresses calcium, phosphorus, and magnesium co-testing. It demonstrates that commercial payers produce parallel but distinct policies, so never assume Medicare LCD rules apply to commercial claims.
• Quest Diagnostics MLCP alignment: Quest Diagnostics publishes a Medical Laboratory Coverage Policy (MLCP) aligned to LCD L34018 under the JN-FCSO jurisdiction. Reference labs routinely apply LCD criteria before processing orders from referring providers.
• Documentation anchor in the ordering note: CMS Article A57122 requires the ordering provider’s clinical indication to appear in the medical record. A lab requisition is not sufficient on its own.

2026 Medicare fee schedule: CPT Code 83970 reimbursement rate

The Medicare Clinical Laboratory Fee Schedule (CLFS) prices CPT Code 83970, and the Protecting Access to Medicare Act (PAMA) governs that schedule. PAMA pricing uses weighted median private payer rates that laboratories report, and CMS resets the rates on a three-year cycle. Verify the 2026 national payment rate for 83970 directly against the published CMS fee schedule lookup tool. Rates adjust annually and vary by clinical setting.

Two practical points for billing managers. First, commercial payer contracted rates for 83970 often differ a lot from the Medicare rate – sometimes higher, sometimes lower depending on the payer contract. Second, bill CLFS codes on a CMS-1500 or 837P claim with a date-of-service equal to the collection date, not the reporting date. Pabau’s integration with Claim.MD supports electronic claims via Claim.MD to over 4,000 US payers, with built-in CPT catalogues that flag code-level edits before submission. Understanding how electronic remittance advice works helps practices reconcile CLFS payments against expected rates quickly when discrepancies arise.

Stop 83970 denials before they start

Pabau’s claims management module connects coding, documentation, and clearinghouse submission in one workflow. Pair the right diagnosis code to every lab order and catch edits before claims leave your practice.

Book a demo

Commonly confused and co-billed codes

Billers routinely confuse several codes with 83970 or bill them alongside it on the same date of service. The distinction between 83970 and intraoperative PTH monitoring matters most. Using the wrong code in a surgical context is a material billing error that attracts audit attention.

Claim denial reasons for CPT 83970 and how to prevent them

Most 83970 denials fall into a short list of recurring patterns. Addressing them at the front end of the revenue cycle costs far less than working remittances after the fact. Effective denial management starts with identifying which pattern is generating the most volume in your practice.

• Non-covered or missing ICD-10 code: The most common denial. The ICD-10-CM code submitted isn’t on the LCD L34018 covered list, or it’s missing from the claim. Corrective action: crosswalk the diagnosis code against the covered list at order entry, before you finalize the order.
• Frequency limit exceeded: LCD L34018 restricts how often you can test PTH in CKD patients per benefit period. Billing a second test within that window without an ABN on file triggers a coverage denial. Corrective action: track PTH test dates per patient and flag orders approaching the limit.
• Missing advance beneficiary notice (ABN): When you order a test outside covered indications and don’t obtain an ABN, you cannot bill the patient — the practice absorbs the cost. Corrective action: issue a CMS-R-131 ABN whenever the diagnosis doesn’t clearly meet LCD criteria.
• No documented clinical indication: A lab order without a note explaining why the clinician ordered PTH isn’t self-documenting. Corrective action: require ordering providers to include a clinical indication in every electronic order.
• 83970 billed when 83519 applies: Intraoperative PTH monitoring during parathyroid surgery is a distinct service from 83970. Corrective action: verify the clinical setting at the point of coding, not after you submit the claim.

Understanding common denial codes in medical billing helps coding teams map remittance adjustment reason codes (CARCs) back to these root causes. Practices using Pabau’s claims management software can configure code-level editing rules that surface these denial triggers before a claim leaves the practice.

Documentation requirements for successful 83970 billing

Thorough documentation is the single most reliable defense against 83970 audit exposure. The ordering provider’s note must give a reviewer enough information to confirm medical necessity without extra explanation. That’s why medical billing compliance practices emphasize documenting in real time over adding notes later.

What the medical record must contain for each 83970 order:

• Clinical indication: The specific symptom, sign, or prior lab result that prompted the PTH order. An example is a serum calcium of 10.8 mg/dL on the basic metabolic panel from the same visit.
• Diagnosis reflected in the ICD-10 code: The clinical note must support the diagnosis on the claim. A code for primary hyperparathyroidism, for example, requires documentation of the findings that led to it.
• PTH assay type ordered: The ordering note should specify intact PTH (not just “PTH”), which sets it apart from the intraoperative or PTHrP assay.
• For CKD patients – monitoring frequency rationale: NKF KDIGO guidelines define PTH monitoring intervals by CKD stage. Documenting the patient’s current CKD stage alongside the PTH order anchors the test frequency to an evidence-based protocol. This strengthens medical necessity defense during an LCD audit.
• Date of service alignment: The DOS on the claim must match the specimen collection date, not the report date. Mismatches generate technical denials that are avoidable.

Practices that integrate lab ordering directly into their superbill documentation workflow reduce the risk of indication gaps. Staff capture the diagnosis code and the clinical note in the same encounter, instead of reconciling them later.

Prior authorization and advance beneficiary notice considerations

Medicare generally does not require prior authorization for outpatient laboratory tests billed under the Clinical Laboratory Fee Schedule, including CPT Code 83970. The coverage gate for Medicare is medical necessity under LCD L34018, not a pre-authorization step. However, that does not mean you never need authorization.

Three scenarios where you need extra steps:

• ABN when coverage is uncertain: The provider must issue an ABN (CMS form CMS-R-131) before you collect the specimen. This applies when the diagnosis is not on the LCD L34018 covered list, or the frequency would exceed the LCD limit. Without a valid ABN on file, the provider cannot bill the patient if Medicare denies the claim.
• Commercial and managed Medicaid plans: Many commercial payers and managed Medicaid plans do require prior authorization for PTH testing. The requirement varies by plan, state, and benefit design. When you verify insurance eligibility at the time of ordering, check whether PTH testing requires authorization under the patient’s plan.
• BCBS and payer-specific policies: BCBSNC’s coverage policy addresses parathyroid hormone testing, including co-testing with phosphorus, calcium, and magnesium. It shows that commercial payers apply coverage criteria that parallel but do not replicate the Medicare LCD. Always pull that payer’s own policy rather than defaulting to Medicare rules for non-Medicare patients.

The foundations of medical billing consistently emphasize one principle here: a denied claim that needed prior authorization always costs more than the check would have. A two-minute eligibility check at the time of order always catches the requirement first.

How Pabau reduces 83970 denials and documentation gaps

Most 83970 denials come down to one of two problems. Staff never checked a diagnosis code against the LCD L34018 covered list, or a frequency limit went untracked. Practice management software like Pabau closes that gap at the point of order, not after the remittance arrives.

Pabau’s claims management software flags a non-covered ICD-10 pairing before you finalize the lab order. Its digital forms then hold the clinical indication and the ABN on the same patient record the biller sees at claim time. When a claim does deny, the remittance detail stays attached to the original order, so the root cause is visible without pulling three systems together.

Catch 83970 denials before they leave the practice

Pabau pairs the diagnosis code to the lab order, flags frequency and ABN issues at entry, and keeps the documentation trail on one patient record.

Book a demo

Conclusion

CPT Code 83970 denials are almost entirely preventable. The two dominant failure modes are a non-covered ICD-10 code and an exceeded frequency limit. You can address both at the front end of the workflow, before you submit the claim. Getting the diagnosis pairing right and documenting the clinical indication in the ordering note closes most of the denial gap. Verifying authorization requirements for non-Medicare patients closes the rest.

Pabau’s claims management workflow connects lab code entry, diagnosis validation, and clearinghouse submission in a single pipeline. This way, you fix a recurring 83970 denial at its source, instead of reworking it claim by claim. Book a demo to see how Pabau keeps 83970 claims accurate from order entry through remittance.

Continue your research

Need a structured approach to lab billing compliance? Medical billing compliance practices covers the documentation and audit-readiness steps that protect practices across all lab code types.

Want to understand how clearinghouse submission works? How Claim.MD clearinghouse works explains the electronic claims pathway from practice to payer, including edit logic and ERA reconciliation.

Looking for the broader denial prevention framework? Denial management in healthcare walks through the root-cause analysis process that reduces denial volume across an entire revenue cycle.

Frequently asked questions